Currently, therapeutic intervention on the Aβ cascade, including inhibiting APP processing and Aβ production, blocking Aβ aggregation and inhibiting Aβ‐induced neurotoxicity, is among the most prominent options for AD treatment. Here, APP is linked to Alzheimer disease.